4suxxess welcomes you!

Setup. Growth. Restructuring. Turnaround.


At 4suxxess, we offer you a team of business architects dedicated to support your company with services designed to enable you to enhance your competitiveness - whether it’s overcoming barriers to success or developing markets locally and globally.

4suxxess provides experienced executive professionals, with the right skill sets to ensure success in challenging assignments and projects.

PharmaTimes: News RSS

Downturn in the number of cancer cases diagnosed as emergency (Mon, 22 Jan 2018)
Some avenues to cancer diagnosis in the UK seem to be improving, with new data from Public Health England showing a shift in the way new cases are detected.
>> Read More

Biosimilar Avastin wins EU approval (Mon, 22 Jan 2018)
European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region.
>> Read More

Biogen ‘optimistic’ for NHS access to Spinraza (Mon, 22 Jan 2018)
Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales.
>> Read More

Sanofi shells out $11.6bn on Bioverativ (Mon, 22 Jan 2018)
Sanofi is fortifying its presence in the field of blood disorders through the purchase of Bioverativ in a deal valued at some $11.6 billion.
>> Read More

Cancer blood tests detects 8 tumour types (Fri, 19 Jan 2018)
Detects 5 kinds of cancer with no current screening tests for average-risk individuals
>> Read More